What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Lung cancer, Cancer research, Internal medicine, Oncology and Epidermal growth factor receptor are his primary areas of study.
His Lung cancer study integrates concerns from other disciplines, such as Carcinoma, Clinical trial and Adenocarcinoma.
His studies in Cancer research integrate themes in fields like Protein kinase B, Signal transduction, Cell growth, Survivin and Pathology.
His research integrates issues of Gastroenterology and Surgery in his study of Internal medicine.
Isamu Okamoto studied Oncology and Cisplatin that intersect with Leukopenia.
The Gefitinib study which covers Docetaxel that intersects with Rociletinib and Icotinib.
His most cited work include:
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2971 citations)
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (1436 citations)
- Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial (459 citations)
What are the main themes of his work throughout his whole career to date?
Isamu Okamoto spends much of his time researching Internal medicine, Lung cancer, Oncology, Cancer research and Epidermal growth factor receptor.
Isamu Okamoto regularly ties together related areas like Gastroenterology in his Internal medicine studies.
His Lung cancer research integrates issues from Cancer and Surgery.
His study looks at the intersection of Oncology and topics like Clinical endpoint with Docetaxel.
His Cancer research study combines topics in areas such as Tyrosine kinase, Protein kinase B, Signal transduction, Survivin and Tyrosine-kinase inhibitor.
His Epidermal growth factor receptor study combines topics from a wide range of disciplines, such as Mutation, Molecular biology, Adenocarcinoma and Pathology.
He most often published in these fields:
- Internal medicine (63.56%)
- Lung cancer (50.89%)
- Oncology (48.71%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (63.56%)
- Lung cancer (50.89%)
- Oncology (48.71%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Lung cancer, Oncology, Cancer research and Non small cell.
His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Etoposide and Durvalumab.
His Lung cancer research incorporates themes from Epidermal growth factor receptor, Survival rate, Tolerability, Adverse effect and Radiation therapy.
Isamu Okamoto mostly deals with Erlotinib in his studies of Oncology.
His Cancer research research also works with subjects such as
- Immunohistochemistry which is related to area like Cell,
- NEUROD1 which intersects with area such as ASCL1.
His study in Osimertinib is interdisciplinary in nature, drawing from both T790M, Standard treatment and Gefitinib.
Between 2017 and 2021, his most popular works were:
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (1436 citations)
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (302 citations)
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (175 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Isamu Okamoto mostly deals with Internal medicine, Oncology, Lung cancer, Osimertinib and Clinical trial.
His research ties Gastroenterology and Internal medicine together.
His work on Erlotinib, Gefitinib and Pemetrexed is typically connected to In patient as part of general Oncology study, connecting several disciplines of science.
The concepts of his Erlotinib study are interwoven with issues in Bevacizumab and Clinical endpoint.
His Lung cancer research incorporates elements of Survival rate, Adverse effect, Subgroup analysis and Epidermal growth factor receptor.
His research in Epidermal growth factor receptor intersects with topics in Liquid biopsy, Cancer research and Digital polymerase chain reaction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
